Harnessing
the power of the
science of eye movement

The analysis of eye movements has fascinated scientists since 1900s, with tens of thousands of papers analyzing how the central nervous system controls eye movements and how a neurological disease affects their normal behavior.
EVIDENCE BASED

Decades of scientific research

29,000

Scientific publications

 Linking eye movements to neurological disease, over the past 60 years. 

 

Publications on Pubmed
1 in 3 people

Neurological disorder

1 in 3 people suffer from a neurological disorder*.

 

* World Health Organization (WHO), Global Status Report on Neurology, 2025.

CENTRAL SYSTEM MAPPING

Neural circuits for oculomotor control

Distinct regions within the central nervous system are associated with specific oculomotor impairments in characterized ways.

Neural circuits

Cortical

Different cortical areas influence the latencies of reactive saccades (intraparietal and posterior parietal cortex) and voluntary saccades (frontal eye fields and prefrontal cortex). In addition, one area influences the inhibition of reactive saccades (dorsolateral prefrontal cortex), and another area influences saccade sequences (supplementary eye fields).

Eye movements abnormalities related to cortical impairment include:

Saccadic impairment
increased latency (reactive and voluntary) & antisaccade error rate
Fixation impairment
saccadic intrusions (square-wave jerks)*
Pursuit impairment
jerky pursuit with catch-up saccades*

* in a non-specific way.

01 04

Subcortical

Damage to the basal ganglia, involving the dopaminergic pathway, affects the amplitude of saccades, leading to a tendency towards hypometria.

Eye movements abnormalities related to extrapyramidal dysfunction include:

Saccadic impairment
 hypometria
Fixation impairment
saccadic intrusions (square-wave jerks)*
Pursuit impairment
jerky pursuit with catch-up saccades*

* in a non-specific way.

02 04

Cerebellum

Cerebellar impairment affects the precision of saccades and ocular misalignment (ocular motor vermis and fastigal nucleus). It can also affect fixation (flocculus/paraflocculus) and the vestibulo-ocular reflex (nodulus/uvula).

Eye movements abnormalities related to cerebellar impairment include:

Saccadic impairment
dysmetria (hypermetria or hypometria)
Ocular misalignment
esophoria or exophoria
Fixation impairment
nystagmus and saccadic intrusions*
Pursuit impairment
jerky pursuit with catch-up saccades*
Vestibular impairment
impaired vestibulo-ocular reflex (VOR)

* in a non-specific way.

03 04

Brainstem

Damage to the brainstem affects saccade velocity (reticular formation), fixation (substantia nigra), and ocular coordination (superior colliculus).

Eye movements abnormalities related to brainstem impairment include:

Saccadic impairment
dysmetria, reduction of saccade velocity, vertical gaze palsy
Fixation impairment
nystagmus, frequent saccadic intrusions* (square-wave jerks)
Pursuit impairment
jerky pursuit with catch-up saccades*

* in a non-specific way.

04 04

PRECISON MARKERS

Turning eye movements into clinical insights

Eye movements are markers that can help monitor brain health with precision.
Non-invasive Time & resource-efficient Objective & quantified
01

Capture video of eye movements

Eye movements are recorded using high-speed cameras operating at 400 frames per second while patients perform standardized visual tasks (protocols). This ensures precise and reproducible data collection.

02

Generate timecourses of eye position & velocity

Proprietary algorithms track eye position and motion, allowing the extraction of the gaze direction and eye velocity.

03

Extract eye movements biomarkers

Clinically relevant biomarkers are computed and displayed next to reference ranges.

Discover our paradigms

Current research

Research with neuroClues®

Ongoing studies & study projects including neuroClues® technology.

Recruitment completed 04/2024 → ongoing

ICEBERG

Early diagnosis of Parkinson's disease

PI initiated

Study of the factors that predict the onset and progression of Parkinson's disease.

PI
Marie Vidhaillet
n
300 (220 PD / 70 iRBD / 70 HV)
France · Paris Brain Institute
Recruiting 10/2025 → ongoing

TREAT-FGF14

Effect of fampridine in SCA27B patients

PI initiated

A randomized, parallel-arm, double blind, placebo-controlled study to assess the efficacy of fampridine for patients with spinocerebellar ataxia SCA27B caused by a GAA expansion in the FGF14 gene.

PI
Giulia Coarelli
n
70 (SCA27B)
France · Paris Brain Institute
Recruitment completed 03/2026 → ongoing

CONSTANCES

Biomarkers for Early Diagnosis of Neurodegenerative Diseases​

PI initiated

Establish reference values for the biomarkers measured by neuroClues® and collect longitudinal oculomotor data from a large population in order to identify pathological progression trends as early as possible.

PI
A. Elbaz
n
220.000 (General population) ​- 25.000 with neuroClues®
France · Inserm
Recruitment completed 04/2024 → ongoing

NEUROPREMS

Early Diagnosis Neurodegenerative Diseases​

PI initiated

Identify longitudinal changes in multimodal markers of neurodegeneration & neuroinflammation during the presymptomatic phase of neurodegenerative diseases​.

PI
A. Durr / J.C. Corvol
n
1.000 (800 presymptomatic at risk subjects & 200 HV) ​
France · Paris Brain Institute
Recruiting 05/2025 → ongoing

Slow-SPEED UK

Early Parkinson’s Exercise Program to Slow Progression of Disease

PI initiated

This study explores whether a structured exercise program can help slow progression in people with early or prodromal Parkinson’s disease. It also examines related markers as oculomotor biomarkers to better understand disease evolution and treatment response.
PI
V. Azoidou
n
110 (HV with prodromal symptom of PD : hyposmia)
United Kingdom · Queen Mary University

No studies at this stage yet.

WORK WITH US

Interested in doing research with neuroClues? 

Curious about how eye movement analysis can transform your clinical practice and what the latest research reveals?
Contact us

neuroClues is powered by P3Lab SRL
VAT: BE 0750.746.841

Centre Monnet – Av. Jean Monnet, 1 – 1348 Louvain-la-Neuve – Belgium
45 Rue du Jardin Public - 33000 Bordeaux - France

 

Our development is financed with the support of the Walloon Region and the European Innovation Council.
Co-funded_ue     wallonie_v_nb-Converted